An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy

• Percentage of Participants With Response to Erythropoietin Treatment [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  Responders of erythropoietin treatment were defined as participants who achieved at least 1 gram per deciliter (g per dl) rise from Baseline in hemoglobin level during within 4-8 weeks or participants who achieved 12 g per dl hemoglobin level at anytime during the study evaluation period (about 8 weeks of follow-up, hemoglobin level reached to 12 g per dl or participants who received blood transfusion at any time of study period) based on National Comprehensive Cancer Institute (NCCN) V3.2009 practice guideline criteria.
  
  

• Serum Erythropoietin (EPO) Level [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  EPO is a hormone secreted by kidney that helps in formation of red blood cells in bone marrow.
  
  
• C-Reactive Protein (CRP) Level [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  CRP is a acute serum protein released from liver. It is associated with low hemoglobin or erythropoeitin resistance.
  
  
• Serum Hemoglobin Level [ Time Frame: Baseline, Week 1, Week 2, Week 4 and Week 8 ] [ Designated as safety issue: No ]
  Hemoglobin is defined as a substance that carries oxygen and gives blood its red color.
  
  
• Serum Hematocrit Level [ Time Frame: Baseline, Week 1, Week 2, Week 4 and Week 8 ] [ Designated as safety issue: No ]
  Hematocrit is the amount of red blood cells in the blood.
  
  
• Reticulocyte Count [ Time Frame: Baseline, Week 1, Week 2, Week 4 and Week 8 ] [ Designated as safety issue: No ]
  Reticulocytes are immature red blood cells.
  
  
• Serum Ferritin Level [ Time Frame: Baseline, Week 1 and Week 2 ] [ Designated as safety issue: No ]
  Serum ferritin is the amount of ferritin in a participant's blood. Ferritin is a protein that stores iron and allows the body to use iron.
  
  
• Serum Iron Level [ Time Frame: Baseline, Week 1 and Week 2 ] [ Designated as safety issue: No ]
  Serum iron is a test that measures the amount of iron in the blood which is bound to transferrin.
  
  
• Transferring Iron Binding Capacity (TIBC) [ Time Frame: Baseline, Week 1 and Week 2 ] [ Designated as safety issue: No ]
  TIBC is a medical laboratory test that measures the blood's capacity to bind iron with transferrin.
  
  

This is an observational, prospective (study following participants forward in time), multi-center (study conducted in more than 1 center) study to identify the predictive factors that will effectively predict the response to erythropoietin treatment in cancer related anemia participants receiving chemotherapy. The entire duration of study will be approximately 1 year. Participants will primarily be evaluated for achieving at least 1 gram per deciliter (g per dl) rise in hemoglobin (substance that carries oxygen and gives blood its red color) level after receiving erythropoietin treatment based on National Comprehensive Cancer Institute (NCCN) V3.2009 practice guideline criteria. Response to erythropoietin treatment will also be predicted using other independent hematological (related to blood) factors like C-reactive protein (CRP - is an acute serum protein released from liver). It is associated with low hemoglobin [substance that carries oxygen and gives blood its red color] or erythropoietin [hormone secreted by kidney that helps in formation of red blood cells in bone marrow] resistance), erythropoietin (EPO), hemoglobin, hematocrit (amount of red blood cells in blood), reticulocyte (immature red blood cells) count, ferritin (a protein that stores iron and allows the body to use iron), serum iron (iron is in the blood which is bound to transferrin) and transferring iron binding capacity (TIBC), level. Number of blood transfusions and participants' safety will be monitored throughout the study.